T3D Therapeutics
Dr. Farlow is Professor Emeritus of Neurology at Indiana University, Associate Co-Director of the Indiana Alzheimer’s Disease Center, Director Alzheimer Clinical Trials site and contributed to 150 clinical trials. He graduated with MD and Neurology Residency at Indiana University. He is a member of multiple societies and has 300 invited lectures. He is on the editorial boards of MedLink and Current Alzheimer Research. He has 470 abstracts, 460 peer-reviewed articles. His research focuses on clinical trials (lead on trials of tacrine, donepezil, rivastigmine, CAD106), methodology, safety, and characterizing familial dementias (Dominantly Inherited AD, Gerstmann-Straussler-Scheinker disease, and chromosome 17 related dementias.
This person is not in the org chart
This person is not in any offices
T3D Therapeutics
T3D Therapeutics’ mission is to develop its lead drug product candidate, T3D-959, as a potential ‘First-in-Class’ and ‘Best-in-Class’ disease-modifying, breakthrough medicine for the treatment of Alzheimer’s disease with the potential to slow, stop or reverse the course of the disease.